Slaughter and May is advising AOP Health International Management AG on its mandatory cash takeover offer for Shield Therapeutics plc

Slaughter and May is advising AOP Health International Management AG (AOP) on its mandatory cash takeover offer for Shield Therapeutics plc (Shield), which was announced on 4 May 2023.

AOP is a provider of integrated therapy solutions from its headquarters in Vienna, as well as through partners worldwide. AOP operates in the filed of rare and complex diseases, focusing on four areas where it develops, produces and markets innovative solutions in the treatment areas of Haemato-oncology, Cardiology & Pulmonology, Intensive Care and Neurology & Metabolic Disorders. Shield is a commercial stage pharmaceutical company focused on the commercialisation of Accrufer®/Faraccru®, a novel oral iron therapy.